Synthes & Eli Lilly to co-develop osteoporosis drugs

Synthes and Lilly Sign Development and Collaboration Agreement (press release) Synthes, Eli Lilly To Cooperate On Orthopedic Products (WSJ) ZURICH (Dow Jones)--Swiss surgical implant maker Synthes Inc (SYST.VX) Thursday said it had signed an agreement with Eli Lilly and Co. (LLY) to license and co-develop orthopedic products. The deal will focus on patients in surgical and orthopedic treatment, including those with osteoporosis and bone fractures, Synthes said. Through the deal, Synthes will license early-stage compounds from Lilly for use within the orthopedic trauma, spine, craniomaxillofaci...


Unlock the full article and exclusive OrthoStreams insights: in-depth analyses, hot startups, trends, market intel, and Daily Newsletter—for just $1/day.
Subscribe Now—Up your Game !
 

Scroll to Top